Please assess the completion status of the following clinical trial:

Trial Title: Mycobacterium w in Patients With Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with severe sepsis within 48 hours of first organ dysfunction~* Cardiovascular system dysfunction: systolic blood pressure ≤90 mm Hg or the mean arterial pressure ≤70 mm Hg for at least one hour despite adequate fluid resuscitation or the use of vasopressors to maintain a systolic blood pressure or mean arterial pressure of \>90 and \>65 mm Hg, respectively~* Renal dysfunction: urine output \<0.5 ml/kg/hour for two consecutive hours despite adequate fluid resuscitation~* Respiratory system dysfunction: PaO2/FiO2 ≤300 or ≤250 if lung sepsis~* Hematologic dysfunction: platelet count \<100,000/mm3 or decrease by 50% in the three days preceding enrollment~* Unexplained metabolic acidosis: pH ≤7.30~Exclusion Criteria:~* Pregnancy~* Gram-positive culture~* Only fungal infection as source of sepsis~* Patients who received cardiopulmonary resuscitation~* Those on immunosuppressive therapy~* Those unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mycobacterium w group (Type: EXPERIMENTAL): Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
- Best standard care (Type: ACTIVE_COMPARATOR): Best standard care for sepsis

Based on this trial design, predict the completion outcome and termination type (if applicable).